1. Home
  2. STXS vs PBMWW Comparison

STXS vs PBMWW Comparison

Compare STXS & PBMWW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • STXS
  • PBMWW
  • Stock Information
  • Founded
  • STXS 1990
  • PBMWW N/A
  • Country
  • STXS United States
  • PBMWW Canada
  • Employees
  • STXS N/A
  • PBMWW 10
  • Industry
  • STXS Biotechnology: Electromedical & Electrotherapeutic Apparatus
  • PBMWW
  • Sector
  • STXS Health Care
  • PBMWW
  • Exchange
  • STXS Nasdaq
  • PBMWW Nasdaq
  • Market Cap
  • STXS N/A
  • PBMWW N/A
  • IPO Year
  • STXS 2004
  • PBMWW N/A
  • Fundamental
  • Price
  • STXS $2.19
  • PBMWW $0.02
  • Analyst Decision
  • STXS Strong Buy
  • PBMWW
  • Analyst Count
  • STXS 2
  • PBMWW 0
  • Target Price
  • STXS $4.50
  • PBMWW N/A
  • AVG Volume (30 Days)
  • STXS 365.8K
  • PBMWW N/A
  • Earning Date
  • STXS 03-03-2025
  • PBMWW N/A
  • Dividend Yield
  • STXS N/A
  • PBMWW N/A
  • EPS Growth
  • STXS N/A
  • PBMWW N/A
  • EPS
  • STXS N/A
  • PBMWW N/A
  • Revenue
  • STXS $25,143,000.00
  • PBMWW N/A
  • Revenue This Year
  • STXS $3.73
  • PBMWW N/A
  • Revenue Next Year
  • STXS $54.27
  • PBMWW N/A
  • P/E Ratio
  • STXS N/A
  • PBMWW N/A
  • Revenue Growth
  • STXS N/A
  • PBMWW N/A
  • 52 Week Low
  • STXS $1.66
  • PBMWW N/A
  • 52 Week High
  • STXS $3.29
  • PBMWW N/A
  • Technical
  • Relative Strength Index (RSI)
  • STXS 48.68
  • PBMWW N/A
  • Support Level
  • STXS $2.21
  • PBMWW N/A
  • Resistance Level
  • STXS $2.17
  • PBMWW N/A
  • Average True Range (ATR)
  • STXS 0.14
  • PBMWW 0.00
  • MACD
  • STXS -0.02
  • PBMWW 0.00
  • Stochastic Oscillator
  • STXS 23.19
  • PBMWW 0.00

About PBMWW Psyence Biomedical Ltd. Warrant

Psyence Biomedical Ltd is a life science biotechnology company pioneering the use of natural psychedelics in mental health and wellbeing. It develops natural psilocybin products for the healing of psychological trauma and its mental health consequences in the context of palliative care. The company has commenced the clinical trial process to evaluate the safety and efficacy of its product candidates. It cultivates natural psilocybin mushrooms at its federally licensed facility in Southern Africa. This product is produced for export to its partners across the world to be processed into a standardized encapsulated product.

Share on Social Networks: